Everstage Launches Agent Core: The Agentic Intelligence Layer Unifying Sales Performance Management
"By centralizing business logic in our Agent Core, we're creating an intelligence layer that not only automates workflows, but actually thinks alongside RevOps, Finance, and Sales leaders to drive better decisions.' - Siva Rajamani, CEO, Everstage
Share
The launch introduces four AI agents focused on Incentive Compensation Management (ICM), with additional agents coming soon to support Territory, Quota, and Capacity planning in the months ahead.
'Agent Core isn't just an enhancement—it's a transformation of how sales performance is managed,' said Siva Rajamani, CEO and Co-Founder of Everstage. 'By centralizing business logic in our Agent Core, we're creating an intelligence layer that not only automates workflows, but actually thinks alongside RevOps, Finance, and Sales leaders to drive better decisions.'
Agent Core: The Unified Brain of SPM
The Agent Core, the foundation of Agentic SPM, is designed to understand your unique business logic, orchestrate workflows across Everstage Incentives and Everstage Planning, and facilitate seamless multi-agent collaboration. It houses all configuration, rules, and data flows, enabling every agent, today and in the future, to respond intelligently, accurately, and in context.
Live in August: AI Agents for Everstage Incentives
Agent Core launches with four domain-specific agents that bring immediate impact to incentive compensation operations:
Databook Assistant
Gets Salesforce data ready for commission processing in minutes using natural language prompts to go-live faster and manage data with ease, all while maintaining data consistency.
Commission Assistant
Converts complex commission calculations into simple explanations. This enables reps to self-serve answers with AI-generated statement breakdowns.
Onboarding Assistant
Automatically assigns new hires to plans, Crystal setups, and modules—supporting both new joiners and internal transitions.
Admin Assistant
Routes support queries automatically using intelligent rules, speeding resolution and reducing admin effort.
These agents eliminate manual work, improve accuracy, and build trust across the sales org, all while future-proofing your compensation processes.
Built for the Full SPM Journey
While Everstage AI launches within ICM, it's built for the broader Sales Performance Management lifecycle. The Agent Core will power additional agents dedicated to tasks like:
Compensation plan creation
Data analysis and recommendations
Territory design and optimization
Quota setting and scenario planning
Capacity forecasting and headcount modeling
With these additional agents, teams will be able to plan, execute, and optimize performance strategies within one AI-powered platform.
About Everstage
Everstage is the AI-first Sales Performance Management platform built for RevOps, Finance, and Sales leaders. With integrated solutions for Incentives and Planning, Everstage enables teams to drive profitable growth through revenue transformation with intelligent automation, real-time data, and seamless execution. With a founding team of Revenue Operations experts and customers across four continents, Everstage is transforming how modern teams manage performance. Today, Everstage has over 300 customers and helps companies like Wiley, Trimble, and Diligent, face the modern requirements of sales performance management.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 minutes ago
- Business Wire
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces an increase in resources allocated to the liquidity contract entrusted to Kepler Cheuvreux. On 15 December 2017 Sensorion entered into a Liquidity Contract with Kepler Cheuvreux, modified by amendments dated 7 December 2018 and 15 July 2022 (the " Contract"). This Contract aims to promote the liquidity of the Shares of Sensorion on Euronext Paris. On 14 August 2025, in accordance with Article 4 of AMF Decision No. 2021-01 of 22 June 2021 renewing the establishment of liquidity contracts on equity securities as an accepted market practice, Sensorion increased the resources allocated to the liquidity contract by €60,000. Following this increase in resources, as of 14 August 2025, the following assets appear on the liquidity account: - 206,211 Sensorion Ordinary Shares - €66,965.21 About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022. Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Business Wire
4 hours ago
- Business Wire
ESS Schedules Second Quarter 2025 Financial Results Conference Call
WILSONVILLE, Ore.--(BUSINESS WIRE)--ESS Tech, Inc. (ESS) (NYSE: GWH), a leading manufacturer of iron flow long-duration energy storage (LDES) systems for commercial- and utility-scale applications, today announced that it will hold a conference call on Thursday, August 14, 2025 at 5:00 p.m. EDT to discuss financial results for its second quarter 2025 ended June 30, 2025. The news release announcing the second quarter 2025 financial results will be disseminated on August 14, 2025 after the market closes. Interested parties may join the conference call beginning at 5:00 p.m. EDT on Thursday, August 14, 2025 via telephone by calling (833) 470-1428 in the U.S., or for international callers, by calling +1 (404) 975-4839 and entering conference ID 271308. A telephone replay will be available until August 21, 2025, by dialing (866) 813-9403 in the U.S., or for international callers, +1 (929) 458-6194 with conference ID 482125. A live webcast of the conference call will be available on ESS' Investor Relations website at A replay of the call will be available via the web at About ESS Tech, Inc. At ESS (NYSE: GWH), we deliver safe, sustainable, long-duration energy storage to ensure energy abundance and security. As energy demand continues to grow, our solutions provide essential reliability and resilience to people, communities, and businesses in the United States and throughout the world. Our technology uses earth-abundant iron, salt and water to deliver environmentally safe solutions capable of providing 10+ hours of flexible energy capacity for commercial and utility-scale energy storage applications. Established in 2011, ESS enables project developers, independent power producers, utilities and other large energy users to deploy reliable, sustainable long-duration energy storage solutions. For more information, visit
Business Wire
5 hours ago
- Business Wire
AM Best to Speak in a Session at the 2025 CAS China Insurance Summit
HONG KONG--(BUSINESS WIRE)-- AM Best will participate in a session during the Casualty Actuarial Society's fourth annual China Insurance Summit, taking place on Aug. 22, 2025, at the Mingyu Chengdu Dongda Hotel in Chengdu, China. Christie Lee, senior director, head of analytics, will speak at 2:30 p.m. CST in a session titled, 'Reinsurance Market Development Trends.' Additional AM Best attendees will include Judy Li, market development analyst, and Lucie Huang, senior financial analyst. Participants will be able to attend in-person or virtually. The event will be conducted in Mandarin, with limited sessions in English. This summit will feature an action-packed schedule with a broad range of topics. To learn more about the summit, visit the event website. To schedule a meeting, please contact Judy Li, or James Chan, Copyright © 2025 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
